Roche’s Genentech unit reported superior Phase 3 results for divarasib versus approved therapies in previously treated KRAS G12C non-small-cell lung cancer, using data from the head-to-head Krascendo 1 trial. The company said the analysis showed clinically meaningful and statistically significant improvements in overall survival and progression-free survival over Lumakras (sotorasib) and Krazati (adagrasib), with no new safety signals. Roche said it plans to submit the findings to regulators and present detailed data at an upcoming medical meeting. Breakthrough therapy designation in 2022 and orphan drug designation in 2026 for KRAS G12C NSCLC remain part of divarasib’s regulatory backdrop. The update keeps pressure on the KRAS G12C market as companies compete on potency, selectivity, and durability of response in previously treated patients.